GLP-1R agonists for the prevention of cardiac injury in STEMI patients undergoing PCI: Something new and promising, or not?

IJC Metabolic and Endocrine

Volumn 1, Issue , 2013, Pages 1-3

  Cheng, Xian Wu ^a,b,c   Murohara, Toyoaki ^a   Kuzuya, Masafumi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YANBIAN UNIVERSITY   (China)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST;

BLOOD LEVEL; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL (TOPIC); EDITORIAL; FOLLOW UP; HEART INJURY; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84892663867     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2013.10.003     Document Type: Editorial

References (18)

1. Ravassa S., Zudaire A., Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res 2012, 94:316-323.
2. van der Horst I.C., Zijlstra F., van 't Hof A.W., et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003, 42:784-791.
3. Timmers L., Henriques J.P., de Kleijn D.P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
4. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
5. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
6. Lonborg J., Kelbaek H., Vejlstrup N., et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012, 201(5):288-295.
7. Lonborg J., Vejlstrup N., Kelbaek H., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012, 33:1491-1499.
8. Read P.A., Hoole S.P., White P.A., et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011, 4:266-272.
9. Ha S.J., Kim W., Woo J.S., et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol 2012, 32:474-480.
10. Kim M., Platt M.J., Shibasaki T., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013, 19:567-575.
11. Matsubara J., Sugiyama S., Sugamura K., et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012, 59:265-276.
12. Monji A., Mitsui T., Bando Y.K., Aoyama M., Shigeta T., Murohara T. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 2013, 305:H295-H304.
13. Woo J.S., Weon K., Ha S.J., et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013, 33:2252-2260.
14. Cheng X.W., Kikuchi R., Ishii H., et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis 2013, 228:211-216.
15. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004, 116(Suppl. 6A):9S-16S.
16. Shigeta T., Aoyama M., Bando Y.K., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012, 126:1838-1851.
17. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
18. Norris S.L., Lee N., Thakurta S., Chan B.K. Exenatide efficacy and safety: a systematic review. Diabet Med 2009, 26:837-846.